The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? - Wikidata - wikimedia - TriplyDB

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

http://www.wikidata.org/entity/Q34360342

about

Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells Histone modifications and nuclear architecture: a review Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds Role of ND10 nuclear bodies in the chromatin repression of HSV-1 Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest.Functional analysis and identification of cis-regulatory elements of human chromosome 21 gene promoters Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors.HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.Chromatin structure exhibits spatio-temporal heterogeneity within the cell nucleus.High-frequency epigenetic repression and silencing of retroviruses can be antagonized by histone deacetylase inhibitors and transcriptional activators, but uniform reactivation in cell clones is restricted by additional mechanisms.Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology.Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?Deacetylation of H4-K16Ac and heterochromatin assembly in senescence.Dietary agents as histone deacetylase inhibitors.Identification of cellular proteins that maintain retroviral epigenetic silencing: evidence for an antiviral response.HDAC inhibitors in experimental liver and kidney fibrosis.Development of histone deacetylase inhibitors for cancer treatment.Tissue-specific effects of valproic acid on DNA repair genes and apoptosis in postimplantation mouse embryos.Molecular dynamics of histone H1.Cancer stem cells and cancer therapy.Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.Impact of Epigenetic Dietary Components on Cancer through Histone Modifications.Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties.E-Cadherin/β-Catenin Complex: A Target for Anticancer and Antimetastasis Plants/Plant-derived Compounds.Analysis of HP1α regulation in human breast cancer cells.Stable morphology, but dynamic internal reorganisation, of interphase human chromosomes in living cells.Post-Translational Modifications of Histones in Human Sperm.The epigenetic modifiers 5-aza-2'-deoxycytidine and trichostatin A influence adipocyte differentiation in human mesenchymal stem cells.Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis Novel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3).Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy.Opposite effects of Trichostatin A on activation of mast cells by different stimulants.Histone deacetylase inhibition accelerates the early events of stem cell differentiation: transcriptomic and epigenetic analysis.Nucleoporins redistribute inside the nucleus after cell cycle arrest induced by histone deacetylases inhibition.Characterization of the Drosophila melanogaster genome at the nuclear lamina.Differential Response of Human Hepatocyte Chromatin to HDAC Inhibitors as a Function of Microenvironmental Glucose Level.

P2860

Q24642670-985BCB6E-C0C0-4220-B0AA-D525FB9FCA3E Q24647743-4210CAE5-290F-4F8E-8AF9-19B3E915D3A7 Q26747518-5E4ED26B-1E69-4F2D-9367-A5A180161262 Q26751443-67339D6C-86B5-4519-BAA8-3130EBEBEB76 Q28257534-ADE34010-922B-4861-8FCC-530053DC3CA3 Q33615259-A6D7D896-32A6-4A98-8991-6B3D88F44D39 Q34189256-0F0F9174-FC47-4086-84B0-DC8D2CF93330 Q34305840-DDA0A7C7-295D-443B-8465-484DBF2DF4EC Q34555935-FE01423B-051C-4590-8306-D462FC5CCCED Q34749665-01530555-0076-49A8-9C75-FD7C40F567FB Q35012357-30FC7015-9E4D-491C-9615-4802A9EEC9CE Q35784937-D9277F63-148A-49C2-B2A4-A651420FEE00 Q35840700-A9924B04-1B82-4B5C-A2AB-46AD3939AEB1 Q36042059-9D3F6C00-FDA1-48A9-9255-0142A3543763 Q36305199-1211E765-44DF-4278-B15A-AF919FFC6A4A Q36367732-DC34F9AA-21B3-42A7-85B6-5E44F63459EF Q36465484-1510EA5E-8ECC-4866-8005-6F1599AE6045 Q36483968-CBC545DB-6D15-4128-BF08-6D731B498441 Q36588493-19B21EE6-9D27-4392-9363-77C36D5DDB2F Q36788512-0694066F-8D74-4662-99D8-1A00C3680736 Q36801900-27519171-9492-4386-8FD0-1F09AB18A219 Q37398631-D22A35CE-4688-4358-AD2D-F4B15C464B69 Q37841186-C8CDE804-3D07-404A-A569-0A38AB95416E Q37978771-CC218062-81D9-4B15-92B8-707ED3CB19BB Q38204487-B8D4A268-3796-433A-B8E0-4E1C5ECD7FC8 Q38428453-3ECFC4F3-E014-4C87-B623-76D3DB34F50A Q38865033-3BA24AE4-9FED-4A93-8570-C35FC76DE9A0 Q39317906-20B52616-9FB4-4BC9-8304-DCBB98F8A425 Q39581442-339CB031-B813-4F6C-A277-FC40D0A1E1F8 Q39678226-F7DB5C38-E47C-4DD6-9DC1-5A10D2B80901 Q41161231-E3B4DB38-3BCB-4A1F-82C0-77563D57899B Q42022435-5CCC3CA5-86F0-451D-9AC1-02FC2239724D Q42152110-ACED1546-0BAA-485A-A35B-77AC9A2C4B51 Q42659391-8EC27A8B-8060-4194-9CD3-2FEADBEF5C6C Q43096605-449D70F4-0D94-4DEA-920E-71ACE25CCD14 Q43108191-70C94142-9989-48DE-B521-01111490262C Q43179522-AFFAFFAC-1F57-41D4-8E26-C3FFC167CB5A Q48144118-5F08B015-7EA5-49DB-9C47-8CA2F51A3C96 Q52670843-9E6A29D9-C110-484A-A74E-2AAF6CA392CA Q52884352-4EF0084B-6754-4A5E-8D64-6BF5F351F58F

P2860

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

http://www.wikidata.org/entity/Q34360342

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

The effects of histone deacety ...... ations for anticancer therapy?

@ast

The effects of histone deacety ...... ations for anticancer therapy?

@en

The effects of histone deacety ...... ations for anticancer therapy?

@nl

type

label

The effects of histone deacety ...... ations for anticancer therapy?

@ast

The effects of histone deacety ...... ations for anticancer therapy?

@en

The effects of histone deacety ...... ations for anticancer therapy?

@nl

prefLabel

The effects of histone deacety ...... ations for anticancer therapy?

@ast

The effects of histone deacety ...... ations for anticancer therapy?

@en

The effects of histone deacety ...... ations for anticancer therapy?

@nl

P1433

Q34360342-58E24EB4-B0AF-4B3D-83DA-42B9EC9BA5DA

P1476

Q34360342-562D7F7C-3BD6-4945-BBEE-A7BF5025DA30

P2093

Q34360342-27305194-340A-4B02-B2D5-B3B8448B44DF

Q34360342-81899F59-919D-442A-950C-828D965555DA

Q34360342-C3F29F4A-9BE5-4C68-852D-A6805D077091

P2860

Q34360342-0BCBBD88-8809-4568-86EF-592D7C3B3A24

Q34360342-0E3ECB34-3E5D-4112-8BAB-01040E2B24A2

Q34360342-257291CA-5A01-4B6C-ABB1-E44F6CBF4EC9

Q34360342-258AF8FD-3D2E-49B8-93E5-B7A3A5181A98

Q34360342-25F083A6-EAF0-47B4-BE45-534F7643D1DE

Q34360342-3D0CBE19-6FA3-4A70-972C-77BC897C0855

Q34360342-41D2630D-8603-45DE-A5F3-6A582968A967

Q34360342-4988328F-BE14-45C5-8B43-B98235F2102B

Q34360342-59033086-FE83-419A-BF3A-E9A4A8F83F5C

Q34360342-59235370-812B-4836-A294-6CB666ECC091

P304

Q34360342-CCCCC752-C34D-421D-A4D3-8D93E7C66848

P31

Q34360342-E72393F0-9B80-4AAD-A86E-8D5C38AF9DB6

P356

Q34360342-18FD0421-7F94-49EF-BA46-4C3D295E501A

P433

Q34360342-F45C4AF5-C000-4703-B016-DAB662E96DB4

P478

Q34360342-8856BC00-24BB-4BE1-A770-391E3F70965B

P50

Q34360342-08D79AE9-63FD-46BE-8A55-57B62A63D3BE

P577

Q34360342-752FA874-A019-4555-B110-82AA2572A6CF

P5875

Q34360342-59A7CAE3-1DAA-4F17-943D-BEB7F6AF877F

P698

Q34360342-FFE1955F-AA84-4171-AEFC-8A6874DAE4B6

P932

Q34360342-EE237371-5C74-4DFE-B077-2DA46F4DBCFF

P356

SJ.EMBOR.7400441

P1433

P1476

The effects of histone deacety ...... ations for anticancer therapy?

@en

P2093

Angela Taddei

http://www.w3.org/2001/XMLSchema#string

Danièle Roche

http://www.w3.org/2001/XMLSchema#string

Wendy A Bickmore

http://www.w3.org/2001/XMLSchema#string

P2860

Translating the Histone Code

BRCA1 supports XIST RNA concentration on the inactive X chromosome

Histone deacetylases (HDACs): characterization of the classical HDAC family

Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

Clinical development of histone deacetylase inhibitors as anticancer agents

Analysis of mammalian proteins involved in chromatin modification reveals new metaphase centromeric proteins and distinct chromosomal distribution patterns

Histone variants: deviants?

Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases.

Histone H3.3 is enriched in covalent modifications associated with active chromatin.

P304

520-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.EMBOR.7400441

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Geneviève Almouzni

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7802640

http://www.w3.org/2001/XMLSchema#string

P698

15940285

http://www.w3.org/2001/XMLSchema#string

P932

1369099

http://www.w3.org/2001/XMLSchema#string